Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Rheumatology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Rheumatology

Journal Scan / Research · October 04, 2022

Anti-Sp4 Autoantibodies Are Associated With Decreased Cancer Risk in Patients With Dermatomyositis With Anti-TIF1γ Autoantibodies

Annals of the Rheumatic Diseases


Additional Info

Annals of the Rheumatic Diseases
Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies
Ann. Rheum. Dis 2022 Aug 25;[EPub Ahead of Print], Y Hosono, B Sie, I Pinal-Fernandez, K Pak, CA Mecoli, M Casal-Dominguez, BM Warner, MJ Kaplan, J Albayda, S Danoff, TE Lloyd, JJ Paik, E Tiniakou, R Aggarwal, CV Oddis, S Moghadam-Kia, C Carmona-Rivera, JC Milisenda, JM Grau-Junyent, A Selva-O'Callaghan, L Christopher-Stine, HB Larman, AL Mammen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading